Geographic atrophy went from having no treatment at all to having two approved options within a single year, 2023. That should be an unambiguous win, and in some ways it is. But there's a genuine, still-unresolved debate among retina specialists about whether these drugs help patients in a way that actually matters day to day, since neither has been shown to preserve vision, only to slow how fast the damage spreads. This piece looks at that debate honestly, and at what's coming next to try to resolve it.
Looking for treatment options for geographic atrophy?
Browse open geographic atrophy clinical trials near you! We'll handle the follow-up.
What's approved right now
Pegcetacoplan (Syfovre), approved by the FDA on February 17, 2023, and avacincaptad pegol (Izervay), approved August 4, 2023, both work by calming an overactive part of the immune system called the complement cascade, just at slightly different points in that cascade. Both are given as regular eye injections, and both were shown in large trials to slow the rate at which geographic atrophy lesions grow, by roughly 15 to 30% depending on the specific trial and dosing schedule.
The debate almost no patient hears about
Here's something that often gets left out of a quick office visit: slowing lesion growth on a scan is not the same as preserving vision. In the trials that led to both approvals, patients on the drugs did not see a meaningful improvement in how well they could actually see, at least not within the one to two years the trials measured.
Some retina specialists see this as a real breakthrough, worth the regular injections and modest risks. Others say the excitement around these drugs goes beyond what the evidence actually shows, and only recommend them to patients who understand the limits and still want to move forward. Both views come from serious, respected specialists, which is why this is still one of the more heated debates in ophthalmology, not a settled question.
What researchers are studying now
A large Phase 3 trial called ARCHER II, testing a drug called vonaprument, enrolled 659 participants and is expected to report results in the second half of 2026, though it's no longer accepting new participants. Beyond complement inhibition, researchers are also testing gene therapy approaches designed to deliver a longer-lasting effect from a single treatment rather than repeated injections, and oral medicines that could replace eye injections entirely by targeting the complement cascade further upstream.
Why geographic atrophy research is unusually contentious
The endpoint problem. Both approved drugs were cleared based on an anatomic endpoint, lesion size on an imaging scan, not a functional one, how well someone can actually see. Regulators accepted that anatomic measure as a reasonable stand-in, but not every doctor agrees that slower lesion growth reliably predicts a real-world visual benefit down the road.
The burden-versus-benefit problem. These treatments mean monthly or near-monthly eye injections indefinitely, with real risks including a small chance of inflammation and, notably, an increased risk of the disease converting to the wet form of macular degeneration. Weighing an ongoing burden against a benefit that hasn't yet been shown to reach vision itself is a genuinely difficult calculation, and different doctors land in different places.
The years-long horizon problem. Because geographic atrophy usually progresses slowly, over years, proving a real difference in long-term visual outcomes takes correspondingly long follow-up. The field is still waiting for that longer-term data to settle the debate one way or the other.
Does geographic atrophy affect more than central vision?
For many patients, yes, in ways that go beyond a vision chart. Losing central vision can affect the ability to drive, read, or recognize faces, even when peripheral vision stays intact, which can be genuinely disorienting and isolating. If the emotional impact of vision changes is affecting your daily life, that's worth raising with your ophthalmologist or a low-vision specialist, who can point you toward practical support, not just medical treatment.
Common myths, cleared up
"An approved drug means it restores lost vision."
Neither approved geographic atrophy treatment reverses vision already lost. Both aim only to slow further damage.
"If my doctor doesn't recommend the injections, they're behind on the research."
Given the genuine, ongoing debate described above, a thoughtful doctor declining to recommend treatment for a specific patient isn't necessarily out of date, they may be weighing the same open questions the field itself hasn't resolved.
"Geographic atrophy always leads to complete blindness."
It causes progressive central vision loss, which is serious, but peripheral vision is typically preserved, meaning most patients don't lose all vision entirely.
How to find a geographic atrophy study through our platform
Search current studies by how advanced your geographic atrophy is and which treatment approach they're testing, complement inhibition, gene therapy, or a cell-based approach, since eligibility and what's involved differ a lot between these. Right now, for example, one Phase 3 study is testing OCU410, a gene therapy given as a single treatment, while another is tracking how Izervay performs in real-world clinical practice outside of the original approval trials. Our geographic atrophy clinical trials page always shows recruiting studies. Applying takes about 5 minutes, and a coordinator follows up to confirm fit.
Common questions
If neither approved drug restores vision, why are people still getting the injections? Some patients and doctors decide that slowing further damage is worth the injection burden even without a proven vision benefit yet, especially if there's meaningful vision left to protect. It's a personal decision made with your ophthalmologist, not a universal answer.
Could a gene therapy approach mean fewer injections in the future? That's the goal researchers are working toward, aiming for a treatment that lasts much longer than monthly injections, though these approaches are still in earlier-stage trials and not yet available.
What are the symptoms of geographic atrophy? The most common early sign is difficulty seeing in low light or needing more light to read, followed by blurry or blank spots in the center of your vision over time. Because peripheral vision usually stays intact, some people don't notice symptoms until central vision loss is fairly advanced.
How often will I need eye exams to monitor geographic atrophy? This varies by how active your case is, but many people are monitored every few months with imaging like OCT scans to track lesion size, more frequently if you're on treatment or if changes have been noted recently.
See Geographic Atrophy clinical trials recruiting near you:
Geographic Atrophy Clinical Trials